ATNM stock results show that Actinium Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024 ...

Actinium, Fusion and RayzeBio are all developing radiotherapies involving the radioisotope actinium-225, or 225Ac. RayzeBio and Bristol Myers announced the deal early Tuesday. In a noted released ...

Discover Actinium Pharmaceuticals' patented method using radiolabeled anti-CD45 antibodies to deplete stem cells for genetic therapy in non-cancerous disorders. Learn about the groundbreaking ...

Invest with your heart and your phone with as little as $1 with these ESG and socially responsible investing apps.

NEW YORK, March 26, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other ...

Actinium Pharma – Pivotal Results From Key New Drug In The Fight Against Cancer Sandesh Seth, CEO & Chairman of the Board of Actinium Pharmaceuticals (NASDAQ: ATNM), was recently a guest on ...

Actinium Pharmaceuticals, Inc. (ATNM) announced Thursday that results from the Phase 3 SIERRA trial of Iomab-B were presented in an ...

Actinium Pharmaceuticals (NYSE:ATNM) traded higher on Tuesday as H.C. Wainwright highlighted its buyout potential after its peer in the radiopharma space, Fusion Pharma (FUSN), agreed to be ...

Jason McCarthy has given his Buy rating due to a combination of factors related to Actinium Pharmaceuticals’ financial stability, developmental progress, and potential market opportunities.

Actinium Pharmaceuticals Inc has a consensus price target of $24.8, established from looking at the 21 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...